11. Over-the-Counter Medications (OTCs)
Over-the-counter medicines seem harmless, yet antacids, painkillers and laxatives can quietly reshape the gut environment — especially when taken repeatedly over time.
OTCs – Hidden Modulators of Your Gut Microbiota
Non-prescription medications like antacids, NSAIDs, laxatives, and antihistamines can significantly alter gut microbiota composition [24].
In 1961, a German paediatrician named Widukind Lenz presented evidence to the German pharmaceutical company Chemie Grünenthal that thalidomide – a sedative and antiemetic sold over the counter in West Germany, Britain, and dozens of other countries since 1957 – was causing severe limb malformations in newborns. The drug had been marketed as safe, even for pregnant women. Lenz had connected the epidemic of phocomelia – seal-limb syndrome – to maternal thalidomide use. The drug was withdrawn. The catastrophe led directly to the modern framework of drug regulation: systematic clinical trials, mandatory safety reporting, and the principle that ‘over the counter’ does not mean ‘without biological consequence.’ The over-the-counter category did not exist as a safety judgement before thalidomide; it existed as a commercial one. The thalidomide case forced medicine to confront what self-medication assumes: that compounds consumed without a prescription act only where intended. The gut microbiota was not part of that regulatory reckoning – the field would not exist for another four decades. But antacids, antihistamines, and common analgesics reach the intestinal environment regardless of whether a prescription was written.
The microbiota effects of prescription medications attracted scientific attention partly because of their severity and clinical visibility. Over-the-counter medications received less attention because they are assumed to be safer – but a systematic drug screening study by Maier and colleagues in Nature (2018) found that many OTC drugs, including antacids, antihistamines, and proton pump inhibitors available without prescription, showed in vitro inhibitory effects against gut bacterial strains at concentrations achievable in the gut lumen. [229] Antacids containing calcium carbonate or magnesium hydroxide raise gastric pH, allowing more oral microorganisms to survive gastric transit into the small intestine. The clinical consequence – small intestinal bacterial overgrowth as a complication of chronic antacid use – has been documented in case series. Antihistamines, through their effects on histamine receptors in the gut wall, can alter intestinal motility and mucosal secretion, modifying the ecological conditions for gut bacteria. [236] Laxatives used chronically produce the most consistently documented OTC microbiota effects. A study by Tropini and colleagues published in Cell Host and Microbe in 2018 used osmotic laxatives in mouse models to show that gut microbiota composition changed rapidly with alterations in luminal osmolality – demonstrating that the physical properties of the intestinal environment, not just its biochemical composition, shape which microbes thrive. Human studies of chronic laxative use have found reduced microbial diversity associated with regular stimulant laxative use. [24] The clinical message is not to avoid OTC medications when needed. It is that the assumption of microbiota neutrality is not pharmacologically justified for any class of drugs that reaches the gut lumen in significant concentrations. Patients who use OTC medications chronically deserve the same consideration of microbiota impact as patients on prescription drugs.
Many people treat over-the-counter medicines as simple tools for everyday symptoms, but several common products can change the conditions in which gut microbes live. These effects are usually not dramatic, and they rarely appear overnight. They tend to accumulate when a medication is taken repeatedly, or when several OTC products are combined over time [229].
Acid-suppressing drugs are a clear example. Proton pump inhibitors and antacids raise gastric pH, which reduces the stomach’s normal filtering effect. In observational studies, PPI use is repeatedly linked to shifts in gut microbial composition, including an increased presence of bacteria typically found in the mouth. This does not mean everyone will develop disease, but it helps explain why some patients notice bloating or a change in bowel habits during long-term acid suppression.
It is also important to separate association from certainty. PPIs have been associated with a higher likelihood of small intestinal bacterial overgrowth in some settings, but this is not universal and depends on individual susceptibility and clinical context. When symptoms persist, the practical issue is not a label, but whether acid suppression is still needed at the current dose and duration.
Non-steroidal anti-inflammatory drugs (NSAIDs) affect the gut through different mechanisms. They can impair mucosal defenses and contribute to small-intestinal injury in a dose- and duration-dependent manner. In both experimental and clinical work, NSAIDs are linked to changes in the intestinal microbial community, and these changes may interact with barrier injury and inflammation. For patients, the relevance is straightforward: repeated NSAID use can make the gut more vulnerable, especially when other stressors—dietary changes, illness, or additional medications—are present.
Laxatives can influence the microbiota by changing transit time and water content in the bowel. Because microbial fermentation depends on how long contents remain in the colon, faster transit can shift which microbes thrive and what metabolites are produced. Experimental work also shows that osmotic disturbances, even when temporary, can cause longer-lasting changes in microbial communities. This supports a cautious view of frequent or prolonged laxative use without addressing the underlying cause of constipation.
The case of antihistamines is more indirect. Their most consistent gastrointestinal effects involve motility, appetite, and the day–night rhythm of digestion, particularly with sedating agents. These shifts can change eating patterns and transit, and through that route may influence the microbial environment. The evidence for a direct, predictable microbiota “signature” is weaker here, so the safest statement is that the effect is possible and context-dependent.
What ties these medications together is that they are often used without structured review. For many patients the key question is not whether an OTC drug is “good” or “bad,” but whether the same symptom is being treated repeatedly while the drivers in the background remain unchanged. When heartburn, constipation, or pain becomes chronic, it is worth reassessing the pattern of self-medication rather than simply adding another product.
In clinical practice, the goal is balance. OTC medicines can be valuable, but long-term use benefits from periodic review: confirming the indication, aiming for the lowest effective dose, and paying attention to persistent digestive changes. Because the microbiota responds to repeated exposures, a small adjustment in habits can sometimes reduce symptoms and improve gut resilience without removing effective symptom control.
How to Use OTCs Mindfully to Protect Microbiota
Thoughtful use of over-the-counter medicines begins with recognizing their role as short-term aids rather than substitutes for long-term care. When symptoms become persistent, the underlying causes deserve attention instead of repeated self-medication.
In conditions such as reflux or chronic pain, clinicians often explore non-pharmacological options alongside or before prolonged OTC therapy. Dietary adjustments, meal timing, sleep habits, and stress management can sometimes reduce the need for continuous drug exposure.
Support for gut health during necessary OTC use can include maintaining a balanced, varied diet that naturally provides fermentable fibers and nutrients for the intestinal ecosystem. Such measures aim to stabilize the microbial environment without turning food into another form of medication.
Choosing the lowest effective dose for the shortest reasonable period is a common clinical principle. This approach seeks to preserve symptom control while limiting unnecessary pressure on the mucosal barrier and microbial community.
Awareness of bodily signals remains important. Persistent bloating, changes in bowel rhythm, or new sensitivities may indicate that the current pattern of OTC use deserves reconsideration in consultation with a healthcare professional.
Microbiota Effects
- Proton pump inhibitors are associated with shifts in microbial composition, particularly with a greater representation of bacteria typically found in the oral cavity; effects on overall diversity appear variable across populations [229].
- OTC NSAIDs can weaken mucosal defenses and increase permeability, and these changes may interact with the microbiota, contributing to dysbiosis in a dose- and duration-dependent manner [236].
- Laxatives may reshape the microbial ecosystem by modifying transit time and luminal hydration, thereby influencing fermentation processes rather than exerting direct antibacterial effects.
- OTC antihistamines can influence gut motility and secretory patterns, and through these indirect pathways may alter the microbial environment, although a consistent microbiota pattern has not been established.
- Prolonged, unsupervised OTC use can be one among several factors that favor low-grade intestinal inflammation, especially when combined with dietary imbalance or other medications.
Patient Guidance
- Use OTC medicines only for short-term symptom relief. Avoid turning them into daily habits without medical review.
- If you take a PPI, review the need regularly with your doctor. Do not continue high doses out of routine.
- Be cautious with frequent laxative use. Focus first on fluids, regular meals, and gentle sources of fiber before relying on tablets.
- Do not combine several OTCs without a clear reason, especially pain relievers and acid suppressants.
- Choose the lowest effective dose for the shortest time.
- Drink enough water every day, particularly when using laxatives or pain relievers.
- Watch your gut signals. Report persistent bloating, new bowel changes, or stomach pain to your clinician.
- After stopping an OTC, return gradually to a varied, balanced diet rather than making extreme dietary changes.
- Treat “natural alternatives” as medicines too. Use herbal products only if they suit your condition and other treatments.
- Remember: OTCs are useful tools, not neutral substances. Use them with the same care as prescribed drugs.
References
[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link
Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.
[229] Maier L, Pruteanu M, Kuhn M et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018. Link
This in vitro screening tested >1000 marketed drugs against 40 representative gut bacterial strains and found that 24% of human-targeted drugs across all therapeutic classes inhibited at least one strain. Antipsychotics were overrepresented in this group. Drug effects on gut bacteria correlated with antibiotic-like side effects in humans and matched existing cohort data. Susceptibility to antibiotics and human-targeted drugs correlated across species, indicating shared resistance mechanisms verified for several drugs. The findings raise concern that non-antibiotics may promote antibiotic resistance.
[236] Tropini C, Moss EL, Merrill BD et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell. 2018. Link
This mouse study assessed gut ecosystem resilience to osmotic perturbation across length and timescales. Osmotic stress reproducibly extinguished highly abundant taxa and expanded less prevalent members in human and mouse microbiotas. Quantitative imaging showed mucus-barrier decimation during perturbation, followed by recovery. The immune system displayed transient cytokine changes and a lasting IgG response against commensals. Increased osmolality prevented commensal growth in vitro, revealing one mechanism of extinction. The findings characterize how laxative-like osmotic stress reshapes the gut microbiota and host immunity.